Research by condition
What the studies show
Plain summaries of published trials, with a link to each study. None of these uses is FDA-approved.
Treatment-resistant depression
Depression that has not improved after at least two standard treatments. Psilocybin and 5-MeO-DMT have each been tested in separate trials; neither is an approved treatment.
Major depression
Moderate to severe depression in people who have not necessarily tried other treatments first.
Anxiety and depression with serious illness
Distress, anxiety and depression in people living with life-threatening cancer.
Alcohol use disorder
Problem drinking that is hard to control despite harm.
Quitting smoking
Tobacco dependence in people trying to quit.
PTSD
Post-traumatic stress disorder. Most research has used MDMA; ibogaine has an early open-label study, and controlled psilocybin evidence is limited.
Parkinson's disease
A small open-label pilot trial gave psilocybin to people with Parkinson's disease who also had depression or anxiety. It is the first published study of a psychedelic in any neurodegenerative disease, and it was designed to test safety and feasibility, not to prove benefit.
Alzheimer's disease and dementia
No psychedelic is an approved or established treatment for Alzheimer's disease or dementia. One published human report describes a single person with advanced Alzheimer's, and the trials now recruiting do not test whether psilocybin treats dementia.
General information, not medical advice. Talk to a doctor before any treatment.